SCHEMBL1887752

SCHEMBL1887752

CN1CCN(c2cc(C(N)=O)c(C(=O)Nc3n[nH]c4c3CN(S(=O)(=O)c3cc(F)cc(F)c3)CC4)cc2-n2cccc2C(=O)O)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 4/20 0.61
AURKA O14965 9/20 0.37
AURKB Q96GD4 7/20 0.37
ALK Q9UM73 5/20 0.35
INSR P06213 3/20 0.35
NTRK1 P04629 5/20 0.35
NTRK3 Q16288 3/20 0.35
NTRK2 Q16620 3/20 0.35
GAA P10253 1/20 0.34
ABL1 P00519 4/20 0.34
BCR P11274 3/20 0.34
PLK1 P53350 2/20 0.34
RET P07949 3/20 0.33
FGFR1 P11362 3/20 0.33
KIT P10721 2/20 0.33
FLT3 P36888 2/20 0.33
PLK4 O00444 2/20 0.33
JAK2 O60674 2/20 0.33
MAP4K4 O95819 2/20 0.33
LCK P06239 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888111 0.95 IGF1R (0.54) IGF1RAURKAAURKBALKGAA
SCHEMBL1893525 0.94 IGF1R (0.54) IGF1RAURKAAURKBALKINSR
SCHEMBL1889683 0.94 IGF1R (0.52) IGF1RAURKAAURKBALKNTRK1
SCHEMBL1893131 0.92 IGF1R (0.52) IGF1RNTRK1NTRK3NTRK2GAA
SCHEMBL1892595 0.91 IGF1R (0.47) IGF1RAURKAAURKBALKNTRK1
SCHEMBL1890569 0.89 IGF1R (0.51) IGF1RAURKANTRK1CDK2MET
SCHEMBL1887120 0.89 IGF1R (0.51) IGF1RAURKACDK2MET
SCHEMBL1893580 0.89 IGF1R (0.47) IGF1RAURKAAURKBALKINSR
SCHEMBL1886220 0.89 IGF1R (0.46) IGF1RALKINSRNTRK1NTRK3
SCHEMBL1883530 0.88 IGF1R (0.51) IGF1RAURKAAURKBALKINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US claimed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885AURKA 332/4885AURKB 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.